SYSTEMATIC REVIEW article
Front. Med.
Sec. Gastroenterology
Twelve Chinese Patent Medicines Combined with Conventional Medicine for the Treatment of Functional Dyspepsia: A Network Meta-Analysis
Provisionally accepted
- 1Guangzhou University of Traditional Chinese Medicine Shenzhen Hospital, Shenzhen, China
- 2Shenzhen Traditional Chinese Medicine Hospital, Shenzhen, China
- 3National Key Laboratory of Syndromes of Traditional Chinese Medicine, The First Affiliated Hospital of Guangzhou University of Chinese Medicine, guangzhou, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Background: This study systematically evaluates the clinical efficacy and safety of 12 Chinese Patent Medicines (CPMs) combined with conventional Western medicine (CWM) in treating Functional Dyspepsia (FD), aiming to provide robust evidence for optimizing treatment strategies. Methods We systematically searched eight Chinese and international databases up to September 2025, including China National Knowledge Infrastructure, Wanfang Data, VIP Information, China Biology Medicine Disc, PubMed, Embase, Web of Science, and the Cochrane Library. Risk of bias was assessed using the Cochrane tool, and evidence certainty was appraised with CINeMA. Network meta-analysis was performed within a frequentist framework using random-effects models, and treatments were ranked by the surface under the cumulative ranking curve (SUCRA). Results A total of 76 RCTs involving 7,575 participants were included. All CPM + CWM regimens were more effective than CWM alone. The most significant benefit for total effective rate was observed with Jinghua Weikang Capsules (JWC) + CWM (RR = 1.46, 95% CI 1.28– 1.67; SUCRA = 98.4%), Wuling Capsules (WLC) + CWM (RR = 1.29, 95% CI 1.18 – 1.42; SUCRA = 80.9%), and Qizhi Weitong Granules (QWG) + CWM (RR = 1.26, 95% CI 1.14–1.38; SUCRA = 69.2%). For motilin, WLC + CWM, Zhizhu Kuanzhong Capsules (ZKC) + CWM, and Simo Tang Oral Liquid (STOL) + CWM showed significant improvements. For gastrin, Liuwei Nengxiao Capsules (LNC) + CWM, Dalitong Granules (DLTG) + CWM, and STOL + CWM ranked highest. No CPM + CWM regimen was associated with a significant increase in adverse events, except for a higher risk with WLC + CWM versus QWG + CWM (OR = 4.82, 95% CI 1.02–22.87). Sensitivity analyses and meta-regression supported the robustness of these findings, while CINeMA rated the certainty of evidence as low for most comparisons. Conclusion CPM combined with CWM was more effective than CWM alone in improving symptom response and gastrointestinal hormone levels, without increasing adverse events. These findings support CPMs as promising adjuncts to standard therapy, though higher-quality RCTs are needed to confirm their role in personalized management of functional dyspepsia.
Keywords: functional dyspepsia, Chinese patent medicines, Network meta-analysis, efficacy, Systematic revie w
Received: 21 Jul 2025; Accepted: 13 Nov 2025.
Copyright: © 2025 Han, Wu, Cui, Zhang, Ye, Huang, Lin and Wang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Nanbu Wang, nanbuwang@gzucm.edu.cn
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.